Spoken Alpha
Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences is a blank check company seeking to acquire a healthcare or healthcare-related business, primarily targeting biopharmaceutical, medical device, diagnostics, or specialized healthcare services companies in North America, Britain, or Europe.
Oaktree Acquisition Corp. III Life Sciences.
Behavioral analysis
Disclosures
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add OACCW, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks OACCW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OACCW.
$ curl https://api.spokenalpha.com/v1/companies/OACCWFAQ
Spoken Alpha indexes OACCW's earnings call transcripts at https://spokenalpha.com/companies/OACCW. Each call links to attributed speakers and parsed analyst Q&A.
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.50 | $4.27 | +28.8% | -7.7% | -7.9% |
| Q4 FY2026 | $5.59 | $4.37 | +28.0% | -5.8% | -3.4% |
| Q3 FY2026 | $5.96 | $4.35 | +37.0% | -8.7% | -7.7% |
| Q2 FY2026 | $5.92 | $4.39 | +34.8% | -3.9% | -6.8% |
| Q1 FY2025 | $5.71 | $4.37 | +30.7% | -3.7% | -6.0% |
CEO since 2024 • 5/8 beats (63%) • last guidance cut Q2 FY2026
| Q4 FY2025 |
| $6.14 |
| $4.44 |
| +38.2% |
| -5.3% |
| -5.8% |
| Q3 FY2025 | $6.25 | $4.38 | +42.8% | +1.0% | +3.5% |
| Q2 FY2025 | $5.84 | $4.22 | +38.4% | -3.4% | -6.0% |
| Q1 FY2024 | $5.69 | $4.32 | +31.6% | -9.1% | -10.0% |
| Q4 FY2024 | $5.71 | $4.33 | +31.8% | -5.9% | -4.7% |